It is also safe and well tolerated.<h4>Conclusion</h4>Burosumab represents a safe and efficient treatment in TIO patients, to be administered in case of tumor identification while waiting for surgery, and in case of surgical inoperability to manage hormonal FGF23 effect. The gene discussed is FGF23; the disease is neoplasm.